Cardiac hypertrophy is a common consequence of chronic hypertension and leads to heart failure and premature death. The anion nitrite is now considered as a bioactive molecule able to exert beneficial cardiovascular effects. Previous results showed that nitrite attenuates hypertension-induced increases in reactive oxygen species (ROS) production in the vasculature. Whether antioxidant effects induced by nitrite block critical signaling pathways involved in cardiac hypertrophy induced by hypertension has not been determined yet. The Akt/mTOR signaling pathway is responsible to activate protein synthesis during cardiac remodeling and is activated by increased ROS production, which is commonly found in hypertension. Here, we investigated the effects of nitrite treatment on cardiac remodeling and activation of this hypertrophic signaling pathway in 2 kidney-1 clip (2K1C) hypertension. Sham and 2K1C rats were treated with oral nitrite at 1 or 15 mg/kg for four weeks. Nitrite treatment (15 mg/kg) reduced systolic blood pressure and decreased ROS production in the heart tissue from hypertensive rats. This nitrite dose also blunted hypertension-induced activation of mTOR pathway and cardiac hypertrophy. While the lower nitrite dose (1 mg/kg) did not affect blood pressure, it exerted antioxidant effects and tended to attenuate mTOR pathway activation and cardiac hypertrophy induced by hypertension. Our findings provide strong evidence that nitrite treatment decreases cardiac remodeling induced by hypertension as a result of its antioxidant effects and downregulation of mTOR signaling pathway. This study may help to establish nitrite as an effective therapy in hypertension-induced cardiac hypertrophic remodeling.
Introduction
Hypertension is considered a public-health challenge that affects at least 970 million people worldwide and increases risk of cardiovascular disorders and premature death [1] . Cardiac hypertrophy is a common compensatory response to chronic hypertension that requires increased synthesis of cellular proteins in the cardiomyocyte and frequently becomes maladaptive, thus evolving towards progressive left ventricle dysfunction and heart failure [2] .
The control of the signaling pathways involved in cardiac remodeling represents a potential therapy for cardiac hypertrophy induced by hypertension. In this regard, the anion nitrite has shown promising effects as a modulator of cardiovascular diseases. While nitrite was previously considered an inert oxidative end product of nitric oxide (NO) metabolism [3] , several recent studies have shown that nitrite and nitrate can be recycled back to NO and work as an alternative source of NO in addition to the classical L-arginine-NO synthase (NOS)-NO pathway [4] . This mechanism is relevant, particularly because reduced NO bioavailability is commonly found in patients with cardiovascular diseases and nitrite may act as a therapeutic option to enhance NO bioavailability in the cardiovascular system [5] . In this respect, dietary nitrite reduced systolic blood pressure (SBP) and cardiac hypertrophy and fibrosis in a rat model of hypertension caused by inhibition of endogenous NO production [6] . Moreover, data from our laboratory demonstrated that nitrite treatment exerts antihypertensive [7] and antioxidants effects by inhibiting vascular NADPH oxidase (NOX) activity, thus decreasing excessive concentrations of reactive oxygen species (ROS) and ameliorating renovascular hypertension [8] .
Over the last decade, much research has focused on identifying the signaling pathways that regulate cardiac hypertrophy. The mammalian or mechanistic target of rapamycin (mTOR) pathway plays a crucial role in cell proliferation and organ growth both in physiologic and pathologic conditions [9] . The mTOR is a conserved serine/threonine protein kinase that activates protein synthesis by regulating ribosomal proteins [9] . In accordance with its cellular function, mTOR is a major downstream component of phosphoinositide-3 kinase (PI3K)/Akt (or Protein kinase B) pathway and has been shown to regulate cardiac growth in the response to pressure overload [10] . In fact, rapamycin (a specific inhibitor of mTOR) administration regresses both established compensated and decompensated cardiac hypertrophy induced by aortic constriction in mice [11] . Additionally, mTOR knockout mice have reduced protein synthesis and do not develop compensatory hypertrophy in response to pressure overload, which impairs the capacity of the heart to adapt to stress [12] . mTOR is also required for the initiation and development of cardiac hypertrophy in spontaneously hypertensive rats and pharmacological inhibition of this pathway with rapamycin reduced heart mass and hypertrophy observed in this model [13] . Importantly, many growth factors such as angiotensin II (Ang II) trigger sequential activation of the mTOR signaling and stimulate protein synthesis in cardiomyocytes [14] . However, it is still unknown about the involvement of this pathway in an Ang II-dependent experimental model of hypertension.
Increased ROS production is consistently implicated in the progression of cardiac remodeling. Ang II activates NOX in the heart and increases ROS formation, thus resulting in interstitial collagen deposition, cardiac fibrosis and hypertrophy through Akt/mTOR and nuclear factor kappa B (NFkB) signaling pathway [15] . Conversely, treatment of hypertensive rats with an antioxidant such as tempol attenuated cardiac remodeling by decreasing tumor growth factor beta levels and matrix metalloproteinase activity in the heart [16] . However, although increased oxidative stress is involved in this pathophysiological mechanism, clinical trials have shown that antioxidant drugs are not effective in preventing it, and therefore other therapeutic alternatives must be defined [17] . While mTOR is a ROS-sensitive pathway and participates in hypertension-induced cardiac hypertrophy, the possibility that nitrite therapy and its antioxidant effects could inhibit cardiac hypertrophy by downregulating Akt/mTOR signaling pathway has not been examined. While there is evidence that nitrite therapy may prevent cardiac remodeling in L-NAME-induced hypertension [6] , the authors of this study mentioned that they started nitrite and L-NAME treatments simultaneously, thus requiring further studies to examine whether nitrite could reverse cardiac remodeling [6] .
In the present study, we tested the hypothesis that nitrite attenuates 2K1C hypertension-induced cardiac hypertrophic remodeling by inhibiting ROS formation and downregulating the mTOR signaling pathway. We also investigated whether nitrite therapy at sub-antihypertensive dose attenuates 2K1C hypertension-induced activation of the mTOR pathway and cardiac hypertrophic remodeling.
Materials and methods

Animals, treatments and blood pressure measurement
The animals used in the present study were handled according to the guiding principles published in the National Institutes of Health Guide for the Care and Use of Laboratory Animals and the study followed the guidelines of the Ribeirao Preto Medical School, University of Sao Paulo. Male Wistar rats (180-200 g) obtained from the colony at University of Sao Paulo were maintained on a 12-h light/dark cycle at room temperature (22-25°C) with free access to standard rat chow and water.
Renovascular (2K1C) hypertension was induced as previously described [26, 27] . Briefly, the rats were anesthetized with tribromoethanol (250 mg/kg, i.p.) and had their left renal artery clipped with a silver clip (.2 mm). Sham-operated control rats underwent the same surgical procedure except for the clip placement. The nonsteroidal anti-inflammatory flunixinemeglumine (2.5 mg/kg, s.c., Banamine; Schering Plough, Brazil) was administered after surgery. The animals were randomly assigned to 1 of 5 experimental groups as follows: 2K1C and sham groups that received vehicle (water); sham group that received nitrite 15 mg/kg, 2K1C groups that received nitrite 15 or 1 mg/Kg daily, by gavage. Treatment was started 2 weeks after 2K1C hypertension was induced and maintained for additional 4 weeks. The nitrite doses (15 mg/kg or 1 mg/kg, daily) used in this study were based on previous studies showing significant antihypertensive effects [18, 19] or lack of this effect [6, 20] in hypertensive rats. Tail systolic blood pressure (SBP) was assessed weekly by tail-cuff plethysmography, and rats were considered as hypertensive when SBP increased by 30 mmHg as compared to baseline values two weeks after the surgery. Importantly, last SBP assessment was carried out approximately 18 h after the last dose of nitrite.
Measurement of nitrite concentrations in plasma and heart
The plasma and heart extracts were analyzed in duplicate for their nitrite content using an ozone-based reductive chemiluminescence assay as previously described [21] . The hearts were homogenized in ice-cold phosphate buffer (pH 7.4; 500 μl) and homogenates were kept on ice in the dark and used within 30 min of preparation. Briefly, to measure nitrite concentration, 50 μl of plasma or 200 μl of heart extracts samples were injected into a solution of acidified triiodide, purging with nitrogen in line with a gas phase chemiluminescence NO analyzer (Sievers Model 280 NO analyzer, Boulder, CO, USA). Approximately 8 ml of triiodide solution (2 g potassium iodide and 1.3 g iodine dissolved in 40 ml water with 140 ml acetic acid) was placed in the purge vessel into which the samples were injected. The triiodide solution reduces nitrites to NO gas, which is detected by the NO analyzer. The data were analyzed using the software Origin Lab 6.1.
Harvesting the hearts
The animals were weighed, anesthetized, and the thoracic cavity was opened to expose the still beating heart. The hearts were rapidly removed, rinsed in ice cold 0.9% saline solution, blotted, weighed, and fixed in phosphate-buffered 10% formalin (pH 7.3) for histological study. Both ventricles from each heart were isolated and cut into 2 fragments by a mid-ventricular coronal section and the superior part with the base of the heart was embedded in paraffin blocks. Each block was serially cut in the same direction and 4-μm thick sections were stained with hematoxylin and eosin. Average myocyte diameter was determined from 20 measurements in each ventricle, which were made at a 400 × magnification in longitudinally oriented myofibers [22] . Myocyte diameter was obtained in the region of the nucleus of those cells in which the nuclear envelope was sharply defined at both ends, which corresponds to the nucleus length and to its position at an equal distance from the sides of the myocytes. The measurements were done with the Leica Qwin software (Leica Imaging Systems Ltd., Cambridge, UK) in conjunction with a Leica microscope (Leica DMR, Leica Microsystems Wetzlar GmbH, Wetzlar, Germany), videocamera and an online computer.
Assessment of cardiac ROS levels by dihydroethidium, by lucigeninderived chemiluminescence and lipid peroxidation assays
The oxidative fluorescent dye dihydroethidium (DHE) was used to evaluate in situ production of ROS, as previously detailed [23, 24] . Briefly, cardiac tissues were embedded in Tissue-tek and then frozen and cut in serial 5-μm-thick slices. Unfixed cryosections were incubated at room temperature, in the dark, with 30 μl of DHE (10 μmol/L) for 30 min. Heart tissue from 2K1C untreated group were pretreated with tiron, a superoxide scavenger (1 mmol/L) for 1 h before adding the DHE as a positive control for ROS inhibition. Sections were examined by fluorescence microscopy (Leica imaging Systems Ltd., Cambridge, 
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Free Radical Biology and Medicine 120 (2018) [25] [26] [27] [28] [29] [30] [31] [32] England) using λ ex = 405 nm laser excitation [24] and the image were captured at magnification of 400 ×. Red fluorescence reflected superoxide and non-superoxide production and was evaluated by using Image J software. To further confirm antioxidant effects of nitrite, we measured NADPH-dependent ROS production using lucigenin chemiluminescence assay as previously described [24] . Ventricle homogenates prepared in PBS pH 7.4 (50 μl) were transferred to luminescence microplates, and 175 μl of PBS with lucigenin 5 μmol/L were added. Then background measurement were carried out and NADPH 300 µM was added, and luminescence was measured (Orion II Luminometer, Berthold). Background signals were subtracted from the NADPH-driven signals and reported as relative luminescence units (RLU) mg −1 normalized by dry weight. Cardiac lipid peroxide levels were determined by measuring thiobarbituric acid-reactive substances (TBARS) in heart homogenates using a fluorimetric method, which requires excitation at 515 nm and emission at 553 nm and uses 1,1,3,3-tetramethoxypropane as standard [25] . The lipid peroxide levels were expressed in terms of malondialdehyde and normalized by protein content (µmol/mg).
Western blotting
Left ventricles from 2K1C and sham rats were homogenized on icecold RIPA buffer. Forty micrograms of protein extracts were subject to SDS-PAGE using a 12% polyacrylamide gels. The proteins were then transferred onto polyvinylidene difluoride membranes and blocked with TBS-T (NaCl 100 mmol/L; Tris-Cl 100 mmol/L; Tween 0.1%) containing 5% bovine serum albumin. The membranes were incubated overnight at 4°C with anti-myosin heavy chain (MHC, #ab11083, Abcam), anti-phospho-Akt (Ser473, #9271, Cell Signaling), anti-totalAkt (#9272, Cell Signaling), anti-phospho-mTOR (Ser2448, #5536, Cell Signaling) or anti-total-mTOR (#2983, Cell Signaling) antibodies. Anti-β-actin (MAB1501, Millipore) was used as a loading control. The antibodies were washed in TBS-T and incubated with horseradish peroxidase (HRP)-secondary goat anti-mouse antibody (1:2000, Millipore) or HRP-secondary goat anti-rabbit antibody (1:1000, Millipore) for 1 h. Immunolabeled proteins were visualized using chemiluminescence ECL (Millipore) and registered by ImageQuant 350 detection system (GE Healthcare). The signal intensities were quantified using ImageJ Program (NIH -National Institute of Health).
Statistical analysis
Results are expressed as mean ± S.E.M. Comparisons between groups were assessed by two-way or one way ANOVA followed by the Bonferroni test. A probability value P < 0.05 was considered significant.
Results
Blood pressure responses to nitrite treatment
The SBP increased significantly after two-weeks in 2K1C hypertensive rats, with further increases in the following weeks ( Fig. 1A ; P < 0.05). While nitrite treatment at 15 mg/kg significantly reduced SBP in 2K1C hypertensive rats by about 20 mmHg after the first week of treatment (Fig. 1A , P < 0.05), the lower nitrite dose (1 mg/kg) did not reduce SBP as compared with 2K1C hypertensive rats treated with vehicle (Fig. 1A) . Both doses of nitrite did not affect SBP in Shamoperated rats (Fig. 1A) . While hypertensive rats tended to gain less weight with time, no significant differences were found among experimental groups ( Fig. 1B ; P > 0.05). Fig. 2 shows that nitrite treatment increased nitrite concentrations both in plasma and heart tissue from Sham and 2K1C hypertensive rats (P < 0.05; Fig. 2A and B) , even though the increases in heart tissue 
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Free Radical Biology and Medicine 120 (2018) [25] [26] [27] [28] [29] [30] [31] [32] from 2K1C rats treated with the lower dose of nitrite (1 mg/kg) were not statistically significant (P > 0.05; Fig. 2B ). These data are particularly important because increased cardiac nitrite concentrations could exert antioxidant effects resulting in attenuation of cardiac hypertrophy.
Nitrite attenuates cardiac hypertrophy in hypertension when used at high but not low dose
A major goal of this study was to determine whether nitrite attenuates 2K1C hypertension-induced cardiac hypertrophy, and we found that the administration of nitrite at 15 mg/kg significantly attenuated this alteration commonly found in hypertension. Indeed, nitrite at 15 mg/kg attenuated hypertension-induced increases in heart weight/body weight ratio and myocyte diameter (Fig. 3A , B and B; P < 0.05). Interestingly, the low nitrite dose exerted a similar effect which did not achieve statistical significance (Fig. 3A , B and C; P > 0.05).
Nitrite treatment attenuates the increases in oxidative stress associated with 2K1C hypertension
Increased oxidative stress is a common feature in hypertension, and previous studies have shown that nitrite exerts antioxidant effects in vivo [8, 18] . Our results show that oral nitrite treatment at both doses (1 or 15 mg/kg) attenuated hypertension-induced increases in oxidative stress, as revealed by decreases in DHE fluorescence in nitrite treated hypertensive rats as compared with hypertensive rats treated with water ( Fig. 4A and B ; P < 0.05).
To further validate these results, we used the lucigenin chemiluminescence assay and lipid peroxidation products measurement. In agreement with the DHE results, we found that treatment with nitrite at 15 mg/kg or 1 mg/kg decreased lucigenin chemiluminescence signal in 2K1C hypertensive rats, although this effect was not statistically significant with nitrite at 15 mg/kg ( Fig. 4C ; P < 0.05). Moreover, hypertension increased cardiac MDA levels in the 2K1C group as compared to the Sham vehicle group and nitrite treatment at 15 mg/kg significant decreased this alteration (Fig. 4D , P < 0.05).
Nitrite treatment inhibits signaling pathway involved in hypertensioninduced hypertrophy
Because imbalanced redox conditions associated with increased ROS production promotes hypertrophy by activating Akt/mTOR pathway [15] , we evaluated whether nitrite treatment and antioxidant effects could affect the expression of mTOR signaling. Furthermore, as pathological cardiac hypertrophy is usually associated with re-expression of the fetal gene program such as β-myosin heavy chain (β-MHC or MyH7) [26] , we also examined whether nitrite treatment could prevent this alteration in 2K1C hypertension. Fig. 5A shows increased β-MHC expression in 2K1C untreated animals as compared with Sham-operated animals, and treatment with nitrite at 15 mg/kg blunted this alteration (P < 0.05; Fig. 5A ), whereas nitrite at 1 mg/kg only tended to exert this effect. In parallel with β-MHC expression, we found that 2K1C hypertension upregulated the phosphorylation of both Akt and mTOR (P < 0.05; Fig. 5B and C, respectively) without significant changes in total concentrations of both proteins (P > 0.05; Fig. 5D and E, respectively). Interestingly, nitrite at 15 mg/kg blunted both increases in protein phosphorylation (P < 0.05; Fig. 5B and C, respectively) , whereas the lower dose of nitrite only tended to exert this effect (P > 0.05; Fig. 5B and C, respectively) . Together, these results show that nitrite at 15 mg/kg inhibits cardiac signaling pathways involved in 2K1C-induced cardiac remodeling, whereas the lower dose only tend to exert this effect.
Discussion
The present study shows that chronic nitrite treatment exerts remarkable protective cardiovascular effect as it attenuates cardiac hypertrophic remodeling found in hypertension. This protection was associated with inhibition of ROS production and mTOR signaling transduction pathway, which has been critically implicated in cardiac remodeling. Moreover, while our results clearly show antihypertensive responses with nitrite 15 mg/kg, treatment with the lower dose of nitrite (1 mg/kg), which did not affect blood pressure, tended to attenuate hypertension-induced cardiac hypertrophy, probably as a result of antioxidant effects resulting in less activation of mTOR signaling pathway.
Nitrite was considered as an inactive end product of NO oxidation for many years. However, it is currently regarded as an alternative source of NO in blood and tissues, with promising protective effects against cardiovascular diseases, especially those with impaired NO bioavailability is compromised [5, 27] . In this study, nitrite treatment exerted anti-hypertensive effects associated with significant increases in cardiac nitrite levels, suggesting that tissue nitrite levels may directly promote protective mechanisms against hypertension-induced cardiac remodeling. In fact, it has recently been shown that nitrite treatment downregulates the local renin-angiotensin system and attenuates cardiac remodeling in L-NAME hypertension model [6] , even though nitrite apparently does not inhibit circulating angiotensin converting enzyme activity [28] . While our results agree with previous findings showing that nitrite therapy may prevent cardiac remodeling when nitrite is simultaneously started with L-NAME treatment [6] , our results indicate that nitrite may indeed stop the development of cardiac hypertrophy associated with hypertension. This is because we started nitrite therapy after two weeks of 2K1C hypertension, when there are already significant hypertrophic alterations in the heart, which are attenuated by nitrite therapy and also cardiac hypertrophy keeps on progressing over time in this model of hypertension [29] . Although nitrite supplementation was shown to reduce infarct size and to improve left ventricular function in ischemia-reperfusion model of cardiac injury [30, 31] , the signaling pathways responsible for these beneficial effects are not well understood.
The mTOR signaling is involved in a variety of processes including cell survival, proliferation, differentiation and migration. The main cellular functions of mTOR are exerted by interacting with specific adaptor proteins to form two different multiprotein complexes, mTOR complex 1 (mTORC1), which is activated by PI3K/Akt signaling, and mTOR complex 2 (mTORC2), which is rapamycin resistant in most of the cells and phosphorylates S473 Akt. Inhibition of mTORC1 decreases hypertrophic development, whereas mTORC2 appears to regulate cell survival and polarity [9, 32] . In pulmonary hypertension, mTORC2 is an important regulator of cell survival and proliferation and is positively modulated by NOX4 [33] . In the heart, upregulation of NOX4 causes cardiac remodeling through activating Akt-mTOR and NFκB signaling pathways [15] . mTORC1 activity is increased and promotes cardiomyocyte hypertrophy in models of pressure overload or spontaneous hypertension through marked increase in the synthesis of sarcomeric proteins [9, 13] . Pharmacological inhibition of mTOR can regress chronic and established pressure overload cardiac hypertrophy [10, 11] and mice with specific deletion of cardiac mTOR do not develop compensatory hypertrophy in this model [9] . In this study, we observed increased Akt phosphorylation at S437 in 2K1C untreated rats, thus indicating mTORC2 activation. In fact, we found enhanced mTOR phosphorylation in 2K1C hypertensive rats as compared to Sham-operated animals, and increased mTOR phosphorylation activates mTOR signaling and promotes cardiac hypertrophy. To our knowledge, this is the first study showing that this signaling is upregulated in 2K1C hypertension. This finding agrees with results shown in other animal models of hypertension. For example, Soesanto et al. demonstrated the role of mTOR signaling pathway during spontaneous hypertension-induced cardiac hypertrophy [13] . Moreover, activation of renal mTOR signaling is also increased in DOCA-hypertensive rats, and this pathway is involved in the pathogenesis of kidney injury [34] . Importantly, we observed that nitrite treatment attenuates cardiac hypertrophy in association with inhibited mTOR activation in the heart. Although our data do not show that nitrite directly inhibits mTOR activation, it is highly probable that the inhibitory effect of nitrite on mTOR activation in 2K1C hypertension is mediated by its antioxidant effects. This suggestion is supported by previous findings by Zhao et al. demonstrating that ROS generated by NOX4 in the heart modulates phosphorylation of Akt phosphorylation at S437, an activating site targeted by mTORC2, and upregulates mTORC1 pathway to contribute in the course of cardiac remodeling [15] .
In addition to blunting cardiac mTOR activation, nitrite may have prevented the reactivation of the fetal gene program. The reactivation of cardiac fetal genes such as myocardin, atrial natriuretic peptide, tropomyosin and β-MHC or MyH7 in adult cardiomyocytes, which are usually expressed in the heart before birth, is a useful marker of pathological cardiac hypertrophy [35] . Of relevance to our 2K1C model, Ang II infusion or increased ROS production stimulates the expression of these hypertrophic markers [15] . In agreement with this idea, 2K1C hypertensive rats showed increased cardiac β-MHC expression associated with cardiac hypertrophy, and nitrite treatment blunted the increased expression of this contractile/cytoskeletal protein, an effect that is consistent with the antioxidant responses to nitrite, thus providing another possible mechanism by which nitrite may attenuate cardiac remodeling during 2K1C hypertension. In fact, the 2K1C hypertension model in rats is characterized by augmented ROS production in the heart over time via increased concentrations of Ang II, thus contributing to hypertension-induced left ventricular remodeling in this model [22, 29] . Ang II-dependent hypertension results in upregulation of NOX expression, the main source of ROS, and contributes to the pathogenesis of hypertension. Giving support to this suggestion, Knockout mice for NOX subunits or animals treated with antioxidants do not present increased ROS production, vascular and cardiac remodeling when treated with Ang II [36] . Moreover, inhibiting ROS formation with antioxidant drugs prevents morphological and functional changes induced by 2K1C hypertension [16] . In accordance with this mechanism, we used three different assays to show that nitrite treatment was associated with lower cardiac ROS levels and attenuated lipid peroxidation, which implicates an important mechanism involved in hypertensive cardiac remodeling. This result is consistent with a previous showing that nitrite downregulates vascular NOX activity in 2K1C hypertensive rats [8] and exerts antioxidants effects [7] , even though nitrite itself does not exert direct antioxidant effects [8] . Consistent with our data showing that nitrite decreases cardiac ROS generation in 2K1C hypertensive rats, several studies have shown that nitrite decreases oxidative stress during ischemia-reperfusion injury of the heart [37] , thus suggesting that this is probably a major mechanism by which nitrite protects the heart.
It is now well-established that nitrite mediates a number of beneficial tissue responses, but the downstream molecular signaling pathways underlying these effects are still being elucidated. Nitrite elevates nitrosylation and nitrosation products in tissues which can be responsible for post-translational modifications in a number of proteins [38] and consequent modulation of other key signaling pathways that could play a role in the nitrite effects observed in this study. Although it was not tested in this study, it is well known that nitrite inhibits mitochondrial ROS generation through reversible S-nitrosation of complex I during ischemia-reperfusion [39] . Most likely, the hearts from 2K1C untreated rats present mitochondrial dysfunction and increased mitochondrial ROS production, which could be potentially inhibited by the reduction of nitrite to nitric oxide mediated for example, by heme proteins such as myoglobin, or even by the components of mitochondrial electron transport chain [4] . Finally, we found relatively high levels of nitrite in the plasma and heart from animals treated with nitrite at 15 mg/kg. Although we have not observed any signals of methemoglobinemia in these rats, it might be relevant to measure methemoglobin concentrations before choosing the 15 mg/kg as a therapeutic dose, particularly when designing clinical studies in humans.
In summary, our results provide strong evidence that nitrite treatment decreases cardiac remodeling induced by 2K1C hypertension associated with antioxidants effects and downregulation of mTOR signaling pathway. This study, together with all the findings in the literature, may help to establish nitrite as an effective therapy to treat cardiovascular disease including hypertension-induced cardiac hypertrophic remodeling.
